Asthma Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | GlaxoSmithKline, Chia Tai Tianqing Pharmaceutical Group, AstraZeneca, Oneness Biotech Co., Ltd., Arrowhead Ph

Asthma Pipeline constitutes 80+ key companies continuously working towards developing 90+ Asthma treatment therapies, analyzes DelveInsight.

Asthma Overview:

Asthma is a chronic condition affecting the airways, marked by inflammation and narrowing that leads to symptoms such as shortness of breath, coughing, and wheezing. It often starts in childhood and is commonly linked with other allergic conditions like eczema and hay fever. Asthma encompasses a range of diseases with different phenotypes, and genetic factors, especially a family or personal history of atopy (allergy-prone conditions), are key contributors.

Asthma affects approximately 15-20% of people in developed countries and 2-4% in less developed regions, with children being more commonly affected. Around 40% of children will experience wheezing at some point, which is classified as asthma if it improves with beta-2 agonists, even if lung function tests are normal. Environmental exposures, such as tobacco smoke and particulates, are strongly linked to asthma.

The disease is characterized by acute, reversible inflammation of the airways triggered by irritants or allergens. This causes airway inflammation, increased mucus production, and resistance, particularly during exhalation. Asthma symptoms worsen at night and may include wheezing, cough, and exacerbation by allergies, exercise, or cold air. Asthmatics may also experience other atopic conditions like eczema or hay fever, and some individuals may have nocturnal coughing spells but feel fine during the day.

Request for a detailed insights report on Asthma pipeline insights @ https://www.delveinsight.com/report-store/asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Asthma Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Asthma Therapeutics Market.

Key Takeaways from the Asthma Pipeline Report

DelveInsight's Asthma pipeline report depicts a robust space with 80+ active players working to develop 90+ pipeline therapies for Asthma treatment.
In September 2024, Kinaset Therapeutics shared two oral presentations and a late-breaking poster at the 2024 European Respiratory Society (ERS) Congress. These presentations highlighted the potential of Kinaset's lead clinical candidate, frevecitinib (KN-002), in treating patients with moderate to severe asthma as well as those with COPD.
In May 2024, GSK reported positive headline results from the phase III SWIFT-1 and SWIFT-2 clinical trials. These trials evaluated the efficacy and safety of depemokimab compared to a placebo in adults and adolescents with severe asthma associated with type 2 inflammation, as indicated by elevated blood eosinophil counts.
In April 2024, 25 abstracts on approved and investigational medicines were featured at the American Thoracic Society (ATS) International Conference. Among the highlights were data presentations from Sanofi's immunology pipeline, including the first phase IIb data for rilzabrutinib in moderate to severe asthma.
Key Asthma companies such as GlaxoSmithKline, Chia Tai Tianqing Pharmaceutical Group, AstraZeneca, Oneness Biotech Co., Ltd., Arrowhead Pharmaceuticals, Areteia Therapeutics, Jiangsu HengRui Medicine, SinoMab BioScience Ltd, Incyte Corporation, CSPC ZhongQi Pharmaceutical, Advagene Biopharma Co. Ltd., Beijing Kanova Biopharmaceutical, Inmunotek, Roche, Sanofi, ARS Pharmaceuticals, and others are evaluating new drugs for Asthma to improve the treatment landscape.
Promising Asthma pipeline therapies in various stages of development include GSK3511294, TQC2731, AZD4604, FB704A, ARO-RAGE, and others.

Asthma Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Asthma Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Asthma treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Asthma market.

Download our free sample page report on Asthma pipeline insights @ https://www.delveinsight.com/sample-request/asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Asthma Emerging Drugs

GSK3511294: GlaxoSmithKline
TQC2731: Chia Tai Tianqing Pharmaceutical Group
AZD4604: AstraZeneca
FB704A: Oneness Biotech Co., Ltd.
ARO-RAGE: Arrowhead Pharmaceuticals

Asthma Companies

Approximately 80 key companies are actively working on developing therapies for Asthma. Among them, GlaxoSmithKline stands out with its Asthma drug candidates currently in the most advanced stage of development, namely Phase III.

DelveInsight's report covers around 90+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Asthma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Asthma Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Asthma Therapies and Key Companies: Asthma Clinical Trials and advancements @ https://www.delveinsight.com/report-store/asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Asthma Pipeline Therapeutic Assessment
• Asthma Assessment by Product Type
• Asthma By Stage
• Asthma Assessment by Route of Administration
• Asthma Assessment by Molecule Type

Download Asthma Sample report to know in detail about the Asthma treatment market @ Asthma Therapeutic Assessment @ https://www.delveinsight.com/sample-request/asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Asthma Current Treatment Patterns
4. Asthma - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Asthma Late-Stage Products (Phase-III)
7. Asthma Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Asthma Discontinued Products
13. Asthma Product Profiles
14. Asthma Key Companies
15. Asthma Key Products
16. Dormant and Discontinued Products
17. Asthma Unmet Needs
18. Asthma Future Perspectives
19. Asthma Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Asthma Pipeline Reports Offerings: https://www.delveinsight.com/report-store/asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.